Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME The Company will...
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates...
Immatics Announces Pricing of $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX...
Immatics Announces Proposed $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX...
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming...
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 Houston, Texas and...
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting...
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 Houston, Texas and Tuebingen, Germany, September...
Immatics Announces Second Quarter 2024 Financial Results and Business Update Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in...
Immatics Appoints Alise Reicin to Board of Directors Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX...
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ:...
Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1...
Immatics Announces Full Year 2023 Financial Results and Corporate Update Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in...
Immatics Announces Pricing of $175 Million Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ:...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads